Transcript Highlights:

• Chairman, the substitute preserves the intent of the original bill to ensure only lawful FDA-compliant
• So anything that's not FDA-approved, even those that are, quote, pending, would be out.
• Those that are approved by the FDA. I need to clarify here on the pending piece.
• But I'm glad your bill has incorporated that in the statute, that any FDA-approved only.
• I just want to clarify that it's the FDA-approved only is what your bill is going to leave on the shelves

Bills: SB2101, SB2334, SB2633, SB2637, SB2713, SB2781, SB2782, SB3059, HB 1130

Keywords: minors, sexually explicit materials, public libraries, age verification, civil penalties, library collection review, alcohol storage, airline permits, beverage regulations, airport, commercial flights, alcoholic beverages, local option election, zoning regulations, municipality control, land use, state law, social media, bot accounts, misinformation

Summary: The committee first reopened public testimony on Senate Bill 2713, which concerned protections for freedom of conscience in the context of Realtor association discipline. Texas Realtors representatives testified that their organization is a separate Texas legal entity but affiliated with the National Association of Realtors through a charter and code of ethics. They said Texas Realtors is neutral on SB 2713, that their ethics process is focused on fair housing and equal professional service, and that they have not suspended or terminated anyone in Texas for religious or political speech. Senators pressed them on whether national standards could override Texas law and on examples from other states; the witnesses said state and federal law control and that they would comply with Texas law if the bill passed. Public testimony then closed and SB 2713 was left pending. The committee then took up Senate Bill 1698 on e-cigarettes. Senator Parker explained a committee substitute that tightened enforcement, required distributor registration, expanded regulation to nicotine from any source, added restrictions on child-appealing packaging, authorized inspections and audits, and set compliance deadlines later in 2025 and 2026. After questions, the substitute was adopted and SB 1698, as substituted, was reported favorably to the full Senate on a 6-0 vote, with a recommendation for the local and uncontested calendar. Next, the committee considered Senate Bill 2487 on crisis and mental health facilities. Senator Parker described a substitute that renamed the program a crisis service model, allowed multiple county facilities, added local siting limits, expanded staffing options, shortened clinical timelines, required discharge referrals, directed law enforcement and EMS to transport people there first, and created local boards and expanded reporting. The substitute was adopted and the bill was reported favorably on a 6-0 vote, also recommended for the local and uncontested calendar. Senate Bill 2819, dealing with political activities of county elections administrators, was then reported favorably on a 6-0 vote and likewise sent to the local and uncontested calendar. Senate Bill 2043 was withdrawn. The committee spent substantial time on Senate Bill 2101, which would require municipal public libraries to move sexually explicit materials out of minors’ sections and impose age-verification and review requirements. Supporters argued the bill would protect children from explicit material in public libraries and that libraries should not be left to self-regulate. Opponents, including librarians, parents, authors, and ACLU representatives, argued the definitions were vague, the bill would be costly and burdensome for small libraries, could function as a book ban, and would restrict teens’ access to classics, research materials, and other books. Several witnesses said parents should make those decisions, not the state. The bill’s author said the committee substitute was still being worked on and asked witnesses to review it; public testimony remained open in the portion provided, with no final action on SB 2101 shown.

Transcript Highlights:

• According to the FDA, between 2012 and 2017, there were 1,445 reports of adverse events from the abortion
• According to the FDA, between 2012 and 2017, there were 1,445 reports of adverse events from the abortion
• specifically mifepristone, a common and safe medication abortion drug that was first approved by the FDA
• abortion is safe and effective, and it's the best invasive option for abortion care based on decades of FDA
• We can also go back to what the FDA has to say about these abortion pills.

Summary: The Assembly Health Committee met on April 8 and heard a long series of bills, beginning with AB 54 on medication abortion access. The author and supporters, including the Attorney General’s office and reproductive justice advocates, said the bill would protect California’s medication abortion supply chain and shield providers and manufacturers from civil, criminal, and professional liability. Opponents from the California Family Council argued the bill removes safeguards and increases risks. The bill was moved forward on a committee motion. The committee then heard several reproductive and public health measures, including AB 551 to create a pilot program supporting emergency departments in providing reproductive health services, AB 260 to protect medication abortion access and telehealth, AB 309 to remove sunset dates on laws allowing pharmacy syringe sales and lawful possession of sterile syringes, AB 536 to preserve colorectal cancer screening coverage if federal guidelines are challenged, AB 804 to make housing support services a Medi-Cal benefit, AB 594 to address student health insurance billing and transparency, AB 836 to study and expand the midwifery workforce, AB 1418 to collect data on health coverage for eligible employees, and AB 1500 to maintain and expand the abortion.ca.gov information site. Supporters emphasized access, preventive care, workforce shortages, and public health benefits, while opponents raised concerns about abortion, syringe distribution, and the focus of state resources. Most measures were advanced by committee vote, with roll calls showing broad support and a few no votes from members on some bills. The final bill discussed in the transcript was AB 1037, which would update substance use disorder laws to reflect evidence-based, harm-reduction approaches and remove barriers to treatment. The author and supporters described it as a compassionate response to overdose and treatment access problems, while law enforcement opposition argued it would encourage drug use and endanger communities. The transcript cuts off during testimony on AB 1037, so no final committee action on that bill is shown in the provided text.

Transcript Highlights:

• I'm very encouraged that the FDA is moving forward on scheduling the chemicals to prevent them.
• <00:33:01.039> is<00:33:01.360> moving encouraged that the FDA is moving encouraged
• that the FDA is moving forward<00:33:02.320> on<00:33:02.799> scheduling<00:33:04.240>
• And, um, as far as the intent of the amendment, I do think the FDA will put the kind of regulations in
• And, um, as far as the intent of the amendment, I do think the FDA will put the kind of regulations in

Keywords: 1189, house, all

Transcript Highlights:

• And on this I agree with FDA and DEA and my old institute, NIDA, which in July announced that they're
• And on this I agree with FDA and DEA and And on this I agree with FDA and DEA and my<00:00:32.279>
• Products say kratom derived whatever, and a lot of the increase in adverse events to the CDC and FDA
• to<00:03:53.960> the<00:03:54.080> CDC<00:03:54.680> and<00:03:54.920> FDA
• adverse events to the CDC and FDA adverse events to the CDC and FDA are<00:03:56.720> almost<

Keywords: 1187, senate, all

Transcript Highlights:

• showing extraordinary promise and outperforming currently available treatment options on the path toward FDA
• We cannot wait for an FDA-approved pharmaceutical version of a treatment that readily exists in nature
• . widely available yet currently illegal to access. available treatment options on the path towards FDA
• We cannot wait for an FDA approved pharmaceutical version of a treatment that readily exists in nature

Keywords: 1183, house

Transcript Highlights:

• A reason it's not completely FDA approved is that it's registered with the FDA.
• It is registered with the FDA, though.

Keywords: 958, all

Summary: The committee heard testimony on House Bill 44, also called Landon’s Law, which would allow schools to keep anti-choking devices such as LifeVac and remove liability concerns for schools that have them. Representative Candy Massaroni and other supporters said the bill is intended to provide an added rescue option in choking emergencies, especially for children and students with disabilities, and cited concerns that there are no current procedures to rescue some individuals who use wheelchairs or have disabilities. Testifiers from Equal First Aid and Life Act described the device as noninvasive, non-powered, and available with adult and pediatric masks, saying it works by creating suction to dislodge an object from the airway. They also referenced American Heart Association, CDC, and Red Cross guidance in support of broader availability. Lauren McCubbin, Landon McCubbin’s mother, gave emotional testimony about her son’s life and death, saying he choked on a bouncy ball at Boston Elementary on November 21, 2022 and died despite the presence of a nurse and firefighters. She said the bill is meant to ensure no other family has to experience a similar loss and argued that a LifeVac device might have given her son a chance. Committee members asked for clarification about what the device is and why paramedics did not have it, and the bill’s supporters explained that it is a simple suction device and that some emergency services are only beginning to adopt it. After the testimony, a motion and second were made on the bill. The committee then moved into questions and discussion about the device’s function, FDA registration, and use in schools, but no final vote or other action was stated in the excerpt.

Transcript Highlights:

• There was a recent note from the FDA. This is the FDA. They reviewed the data.
• Um, this FDA number is also from before the pills were available in the form and the like quantity that
• Many of these pills aren't even FDA regulated, being shipped from out of the country with little to no
• We were there to answer her questions, review FDA guidelines, and connect her with vital support and
• That same study revealed that these pills are 22 times more dangerous than what the FDA has reported.

Bills: HB7, SB 8

Keywords: abortion, healthcare, jurisdiction, civil action, qui tam, prohibition, state law, sex designation, restroom access, civil penalties, private civil right of action, women's privacy

Transcript Highlights:

• conditions for chronic debilitating conditions for which<00:32:54.720> other<00:32:54.960> FDA
• <00:32:55.440> approved<00:32:55.840> medications which other FDA approved medications
• which other FDA approved medications have<00:32:56.799> not<00:32:57.519> achieved<00:
• <00:33:48.640> approved<00:33:49.039> medications traditional FDA approved medications
• traditional FDA approved medications have<00:33:50.000> have<00:33:50.320> not<00:33:50.559

Keywords: Public Health and Welfare - Room 216, 24 February, 2026; 3:00 PM, 925, all

Summary: The committee first took House Bill 1637 off the table and adopted a committee substitute amendment narrowing Public Records Act exemptions to records of the child death review panel, maternal mortality review committee, and fetal and infant mortality review panel. Supporters said the exemption was intended to let providers and hospitals speak candidly in closed-door reviews to identify mistakes and prevent future deaths, while critics questioned how the public and legislature would learn the outcomes. The amendment and then the bill as amended were adopted by voice vote. House Bill 479, which would extend temporary licensing timeframes for the psychology board and the board of licensed marriage and family therapists from 30 to 60 days, was then considered. An amendment was adopted clarifying that the bill does not alter existing education, supervised training, or examination requirements. Senator Hill raised concerns that the bill’s language could allow a temporary license to last 365 days even if licensure requirements were not met, and the committee ultimately tabled the bill subject to call so the language could be clarified. The committee also heard House Bill 514, the Mississippi Veterinary Practice Act, which updates the vet-client-patient relationship definition, adds a public member and a certified veterinary technician to the board, removes some fees, and adds title protection for certified veterinary technicians. Witnesses said the changes were meant to support the profession and keep more graduates in-state. The bill passed after questions about the certification’s scope. House Bill 612, authorizing intergovernmental agreements and involving Coast Guard training and installation support services, was tabled subject to call after members said they needed more explanation. Finally, House Bill 1152, the Right to Try the Medical Cannabis Act, was considered. The bill creates a process for patients with chronic, progressive, severely disabling, or terminal illnesses not already covered by the medical cannabis statute to petition the Department of Health for access, with the treating physician initiating the request. An amendment was adopted to clarify that out-of-state patients receiving care in Mississippi are not excluded if they meet the same process and standards. Members then debated unclear language near the end of the bill about which provisions control in case of conflict; the sponsor said the new right-to-try provisions would govern for the covered patients. The discussion continued with examples of conditions that might qualify, such as non-malignant chronic pain syndromes, and the bill remained under consideration as the transcript ended.

Transcript Highlights:

• To ensure only lawful FDA-compliant e-cigarette products are sold in Texas, while adding key protections
• want to make sure, and I'm very supportive, but Your bill specifically limits the vape industry to the FDA
• Those that are approved by the FDA. I need to clarify here on the pending piece.
• But I'm glad your bill is incorporated that in the statute that any FDA approved because that'll take
• We're just trying to address all the children that have access. to clarify it's the FDA approved only

Bills: HB256, HCR19, SB2101, SB2334, SB2633, SB2637, SB2713, SB2781, SB2782, SB3059, HB1130

Keywords: severe weather, adaptation plan, vulnerability assessment, environmental protection, state agencies, federal agents, transparency, law enforcement, identification, public trust, immigration enforcement, HCR 19, Texas concurrent resolution, federal immigration enforcement, masked agents, facial coverings, visible identification, uniforms, badges, name tags

Transcript Highlights:

• In a way, we need to step beyond what the FDA has approved. Texas can do that.
• Senator Schwartner, when you get into the studying of these ultra-processed... foods, and what the FDA
• It's Republican FDA...
• It's Democrat FDAs and what they have allowed in our food sources that you can see in other Western civilization
• and this will force, as you notice I have an advisory committee in there, it is going to force the FDA

Bills: SJR18, SCR9, SCR13, SB10, SB11, SB19, SB20, SB25, SB62, SB260, SB263, SB293, SB314, SB384, SB412, SB441, SB442, SB494, SB523, SB569, SB616, SB688, SB707, SB766, SB842, SB869, SB890, SB914, SB929, SB971, SB992, SB1066, SB1145, SB1621, SJR36, SJR18, SCR9, SCR13, SB616, SB565, SB384, SB372, SB495, SB842, SB971, SB1066, SB929, SB765, SB523, SB62, SB19, SB18, SB666, SB688, SB707, SB888, SB687, SB706, SB847, SB869, SB890, SB992, SB1145, SB494, SB290, SB766, SB11, SB10, SB13, SB263, SB412, SB20, SB441, SB442, SB1621, SB569, SB314, SB25, SB293, SB914, SB260, SB1248, SB740, SB14, SB1006, SB20, SB25, SB260, SB293, SB314, SB384, SB442, SB494, SB616, SB869, SB890, SB929, SB992, SB1145, SB1621, SR232, SR237, SR242, SB16, SB22

Keywords: capital gains, taxation, constitutional amendment, state revenue, individual investment, Supreme Court, judicial independence, Keep Nine, checks and balances, water rights, treaty compliance, Rio Grande, agriculture, drought, international water, Texas water supply, education, Ten Commandments, public schools, religious display

Transcript Highlights:

• world, there's what they call the pedigree, and it's the birth, where the drug you came from, is it an FDA-approved
• that's doing the right thing must have that pedigree to prove that they're getting it from a compliant FDA-approved
• source. to prove that they're getting it from a compliant FDA-approved source.
• that's coming in this country, the xylazine that's coming in, it's, you know, I don't think it has FDA

Keywords: 995, all

Summary: The working group on best practices for oversight and enforcement met for its first session and focused on xylazine, including its legal veterinary uses, its appearance in the illicit drug supply, and whether it should be classified as a controlled substance. Members discussed the distinction between pharmaceutical-grade and non-pharmaceutical-grade xylazine, the role of international/illicit sourcing, and the limits of state-level regulation if the substance is already being added to fentanyl or other drugs outside the Commonwealth. The Department of Public Health representative summarized the agency’s view that scheduling xylazine could follow the “ironclad law of prohibition” and push the market toward other, potentially worse substances, and said DPH opposed straight scheduling in favor of education, support, and harm-reduction approaches. Veterinary members explained how xylazine is used in large-animal and research settings, why it is useful, and why federal-style scheduling could create practical burdens for veterinarians who work in the field. They also described reversal agents such as yohimbine and atipamezole (Antisedan), and noted that xylazine is not commonly used in small-animal practice. Several members raised questions about how much xylazine is actually used legally in Massachusetts, whether boards of pharmacy or distributors could provide useful data, and what other states have done. Arizona and Florida were mentioned as possible examples for further research, along with the need to examine stakeholder opposition and any effects on legitimate veterinary practice. The group agreed to divide into two subgroups: one focused on oversight and regulation of production/distribution, and another on whether xylazine should be classified as a controlled substance and what penalties, if any, should apply. Staff said they would circulate notes, a draft PowerPoint template, and a shared folder, with members asked to submit materials by December 2, draft materials due December 4, and final approval by December 9 ahead of the next public meeting on December 11. The meeting ended with a motion to adjourn, a second, and unanimous closure.

Transcript Highlights:

• Covered services are included, but not limited to, diagnostic testing, FDA-approved hormonal therapies
• Covered services are included, but not limited to, diagnostic testing, FDA-approved hormonal therapies
• bill, we have also made sure that within the substitute, that HRT treatments must be approved by the FDA
• bill, we have also made sure that within the substitute, that HRT treatments must be approved by the FDA

Summary: The Senate received communications from the House listing numerous bills, substitutes, amendments, and concurrent resolutions passed by the House or returned to the Senate, and it also noted a Senate amendment being stricken from House Bill 190. Committee reports were read on a wide range of nominations and bills, including favorable reports on several executive nominations and legislation involving nurse preceptors, voting, agricultural/forestry grants, child care, Title IX coordination, vehicle security devices, dry needling, human remains disposition, child care assistance, autism-related oversight, nursing advancement, correctional oversight, massage and bodywork, probate letters, computer security breaches, automobile insurance, medical debt protection, and technical corrections. The Senate also assigned House Bill 300, House Bill 64, and House Bill 385 to the Finance Committee. The chamber confirmed several gubernatorial nominations by roll call vote, each receiving the required majority: Heidi J. A. Gilmore to the Marijuana Appeals Commission; Lee Wynne and Ruth J. Tucker to the Delaware River and Bay Authority Board; Jennifer R. Hallman and Lindsay E. Alexich to the Professional Standards Board; Jason M. Munion and F. Todd Kulata to the Environmental Appeals Board. The Senate also passed House Substitute 1 for House Bill 383, which changes overtime eligibility for certain DelDOT employees and clarifies covered positions, and Senate Bill 315 with Senate Amendment 1, which revises the Delaware Technical Innovation Program to give the Division of Small Business more flexibility in using federal grant funds. Consent Agenda M passed unanimously, including Senate Substitute 1 for Senate Bill 319 on menopause and perimenopause coverage, House Bill 411 on alcohol/tobacco/marijuana enforcement, House Bill 271 on marijuana establishment spacing, House Bill 258 on alcohol licenses, House Bill 303 on juvenile probation/parole officers and DCYF employees, and House Bill 377 on Ocean View municipal election deadlines. Consent Calendar 63 also passed unanimously, including resolutions recognizing Day of Service, National Adoption Month, National Coaches Day, Free Speech Week, Women’s Equality Day, and Spirit of America 250, along with resolutions encouraging a veteran cemetery in Kent County, seeking plans for repurposing underused public buildings, and honoring Delaware Boys State. The Senate spent significant time on floor remarks about the Boys State delegates and on a tribute to emergency responders who helped save a seven-year-old child trapped by a seatbelt; the responders were recognized individually and thanked for their work. Additional remarks explained the purpose of the menopause coverage bill, the adoption month resolution, the free speech resolution, and the America 250 resolution. The session ended with no further business and the Senate recessed until June 18.

Transcript Highlights:

• fellow at the American Enterprise Institute, where he researches and focuses on healthcare competition, FDA
• In fact, if you look at the FDA structure, these staff are actually paid for largely by user fees from
• Administration, the terminations of lots of FDA staff might make some sense, but beyond just the immediate
• If you're looking at any other goals, including FDA approval, rapid approval of drugs and devices, these

Keywords: artificial intelligence, waste reduction, fraud prevention, government efficiency, improper payments, data reliability, oversight

Summary: The meeting was chaired by Chairman Schweikert and involved a comprehensive discussion on how to utilize artificial intelligence (AI) for reducing waste, fraud, and improper payments within federal programs. Key witnesses, including Mr. Andrew Canarsa from the Council of the Inspectors General, provided insights on the potential of AI in enhancing government efficiency. The committee emphasized the importance of reliable data and thorough examination of AI application to avoid unintended consequences while addressing the estimated $162 billion in improper payments reported by the federal government. Concerns were raised regarding the recent firing of inspectors general and the impacts that could have on oversight and accountability processes.

Transcript Highlights:

• It allows schools to have any FDA-approved emergency opioid antagonists, and it may, to have any FDA-approved
• It allows school to have any FDA-approved emergency opioid antagonists, and it may, to have any FDA-approved

Summary: The Pre-K Through 12 Budget Subcommittee met with a quorum and considered four bills. CS/HB 1403, by Rep. Yeager, would allow child care facilities to participate in the school guardian program and clarify school perimeter and door security requirements. An amendment clarifying that private security companies would pay for training was adopted, and the bill was reported favorably 11-0. CS/HB 447, the Evan B. Hartzell Act by Rep. Salzman, would provide guidance for schools that choose to teach disability history and awareness during the first two weeks of October, including age-appropriate instruction by grade band. The bill received supportive testimony from advocates and was reported favorably 11-0. CS/HB 257, by Reps. Chambliss and Tramont, would expand on a prior pilot program to allow video cameras in certain self-contained classrooms serving nonverbal students and others with significant disabilities, as a safeguard against abuse and to improve accountability. The bill drew strong support from parents and disability advocates describing abuse concerns, and it was reported favorably 13-0. CS/HB 1255, by Vice Chair Trabulsy, was a broad education bill addressing teacher shortages, scholarship program screening, health and math instruction, corporal punishment policy, and restrictions on spending public funds on organizations tied to discrimination or political/social activism. A major focus of debate was the bill’s human embryologic development instruction and related video language, with supporters calling it science-based and opponents warning it could be medically inaccurate or ideological. After the sponsor said she would amend some language, including removing ABCTE-related text and clarifying the video language, the bill was reported favorably 12-1. The meeting then adjourned.

Transcript Highlights:

• epinephrine injectors or EpiPens and replaces it. with an epinephrine delivery system, basically an FDA-approved
• In August of 2024, the FDA approved a new form of pre-dosed epinephrine, creating the first nasal epinephrine
• epinephrine auto-injectors to be administered in the school setting and need to be amended to reflect the new FDA-approved
• nasal epinephrine and to be inclusive of future FDA-approved pre-dosed epinephrine.

Transcript Highlights:

• Uh, it advertises products as FDA approved when they are not.
• It says you just cannot say they're FDA approved when they're not.
• are not FDA approved.
• This is FDA approved and that you fine.
• their customers that this is not FDA their customers that this is not FDA approved<02:07:34.639>

Keywords: 981, all

Summary: The Senate convened with a quorum, approved the previous day’s journal, and received a long list of bill status reports and enrollments. It also introduced Senate Bill 168, concerning reporting of money handled by legislative caucuses, and Senate Bill 169, a non-substantive revision bill for the Colorado Revised Statutes. The chamber then agreed to proceed out of order for moments of personal privilege and recognized the Denver and Colorado Springs chapters of The Links, Incorporated for Lynx Day at the Capitol. The Senate next took up a special-order consent calendar containing House Bill 1110, Senate Bill 78, and Senate Bill 151. All three committee reports and the bills themselves were adopted without objection, and the Committee of the Whole report was later adopted by a 35-0 vote. As reported, Senate Bill 78 was amended, Senate Bill 151 passed second reading and was ordered engrossed, and House Bill 1110 was amended, passed second reading, and ordered revised for third reading and final passage. The chamber then moved to special orders on Senate Bill 6 and Senate Bill 15, and the transcript focuses mainly on Senate Bill 6, which would require health insurers to offer at least one non-opioid pain medication option. Supporters argued the bill would expand access to safer pain-management alternatives, reduce opioid addiction, and encourage innovation; several members shared personal or professional experiences with opioid harms. Opponents argued the bill would mandate newer, more expensive drugs when less costly alternatives already exist and could raise health care costs. The debate continued in the excerpt, but no final vote on Senate Bill 6 is shown here.

Transcript Highlights:

• Vaping products in Alabama, you have to have applied for a pre-market tobacco application with the FDA
• foremost, this bill is premature given the fact that we are still awaiting a Supreme Court decision in FDA
• This case challenges whether the FDA overstepped its authority. ... in regulating electronic nicotine

Bills: SB210, SB225, HB280, HB287, HB94, HB88, SB157, HB7, HB8, HB42

Keywords: hospital liens, medical billing, government healthcare, insurance claims, patient rights, blood tests, DUI, law enforcement, traffic offenses, chemical analysis, public nuisance, event liability, local government, community health, legal action, transparency, reporting, public safety, regulation, accountability

Transcript Highlights:

• But beyond that, it's really technically this would be an FDA issue, a food safety issue at FDA, not
• But in my mind, this is a federal FDA issue. Representative Hansen, Mr.
• really technically this would be an FDA really technically this would be an FDA issue<01:34:49.239
• <01:34:51.040> not issue a food safety issue at FDA not issue a food safety issue at FDA not
• <01:34:59.159> issue mind this is a federal FDA issue mind this is a federal FDA issue represent

Bills: HF47, HF434, HF1503, HF1702

Keywords: telecommunications, installation, certification, safety, underground utilities, HF434, cervidae, deer, elk, moose, chronic wasting disease, CWD, wildlife importation, animal health, biosecurity, zoo, Association of Zoos and Aquariums, AZA, USDA exhibitor, species survival plan

Transcript Highlights:

• By the way, the FDA currently regulates human cell, tissue, and cellular tissue-based products under
• This bill also refines the scope of practice by permitting podiatric physicians to use certain non-FDA-approved
• But I am curious: does anybody, is the FDA investigating these products, and is it anticipated that at
• some point there will be an FDA approval or disapproval of these products?
• The FDA does do research on all types of products.

Summary: The committee first confirmed six appointees on a single roll-call vote, then took up a series of bills, many of them on land use, housing, public safety, child welfare, education, and professional licensing. Early debate centered on CS/SB 208, which would require development fees to better reflect review costs and impose objective compatibility findings for residential projects. An amendment folded in additional housing-related provisions, including manufactured housing and a study of urban development boundaries, prompting extended discussion about Miami-Dade’s Everglades protection area and local control. A late-filed rural-boundary amendment was withdrawn. The bill was reported favorably after support from business, housing, and advocacy groups, with some senators voicing district-specific concerns. The committee then approved CS/CS/SB 686 on agricultural enclaves after amendments added conservation easement, wildlife corridor, and critical state concern protections, plus a further Everglades-related amendment. Members discussed balancing smart growth, infrastructure costs, and protecting environmentally sensitive areas. Other land-use and growth bills also advanced, including CS/SB 1434 on infill redevelopment, CS/SB 1138 on qualified contractor pre-application review, and SB 218 limiting the reach of prior hurricane recovery zoning protections in counties not affected by the 2024 storms. SB 1474 on biosolids management was amended to reduce the distance threshold for land application restrictions and delay the effective date, and SB 1708 on veterinary licensure by endorsement removed a three-year recent-practice requirement to address shortages. Several public safety, health, and family-related measures also passed. CS/CS/SB 436 expanded felony battery enhancement to include resisting an officer with violence and certain law-enforcement battery offenses. SB 830 extended public-records protections to county and city administrators and related family information. CS/CS/CS/SB 600 revised bail bond rules, and an amendment preserved the current treatment of charitable bail funds and nonprofits; the committee heard testimony from The Bail Project and others on both sides. CS/SB 914 expanded dry-needling supervision options for occupational therapists, CS/SB 1092 clarified podiatric use of certain cellular/tissue products, and SB 1504 and SB 1718 updated insurance licensing and educator certification pathways. On the education side, CS/CS/SB 7038 made broad postsecondary changes, including tuition waivers, residency clarification, and licensure rules, while CS/SB 186 required seizure-response training and action plans in schools. The committee also advanced multiple child welfare and health bills. CS/CS/CS/SB 560 streamlined psychotropic medication procedures for children in state custody and added youth-voice and insurance-review provisions. CS/CS/CS/SB 902 combined several Department of Health changes, including medical marijuana distance rules, autism microcredential eligibility, a neurofibromatosis grant program, and NICU nutrition information. SB 1002 expanded child welfare definitions to address parental drug abuse and neglect, and SB 1708 eased endorsement licensure for out-of-state veterinarians. Most bills were reported favorably on roll-call votes, with several amendments adopted along the way and limited opposition or abstentions noted on some measures.

Transcript Highlights:

• number of psychedelic-assisted therapies that have received breakthrough therapy designation by the FDA
• its head around the implications<01:00:13.720> of<01:00:14.640> the<01:00:14.880> FDA
• approval of a implications of the FDA approval of a number<01:00:17.200> of<01:00:17.800>
• , which means they designation by the FDA, which means they have<01:00:24.760> the<01:00:24.840
• drug development and state FDA drug development and state regulatory<01:20:41.320> processes.

Bills: HB1626, HB1643, HB1668, HB1550, HB1974, HB1858, HB1871, HB1966, HB1972, HB1973

Keywords: youth penalties, juvenile justice, community service, fees and fines, Native Hawaiian, Pacific Islander, reform, court costs, cultural connection, pharmacy, pharmacist, pharmacy audit, audit reform, pharmacy benefit manager, PBM, recoupment, extrapolation, claims audit, pharmacy reimbursement, dispensing fee

Summary: The committee heard testimony on SB 847, which would create a Kauai pilot program allowing qualified psychologists limited authority to prescribe psychotropic medications. The Board of Psychology supported the bill’s intent but asked for amendments to delay the effective date or extend the pilot so rules could be written first, and to clarify the education/training language. Supporters, including the Hawaii Psychological Association, Hawaii Mental Health Coalition, and several psychologists, argued that prescribing psychologists have long safety records in other jurisdictions and that the pilot could improve access to care on Kauai, especially amid ongoing mental health needs and storm-related stress. They cited studies and examples from New Mexico, Louisiana, the Department of Defense, and other places. Opponents, including the Hawaii Medical Association, American Academy of Pediatrics, Queen’s Medical Center, and a Department of Health representative, said the bill needed substantial work, raised concerns about training, liability, and workforce impacts, and urged a team-based model with psychiatrist oversight rather than independent prescribing. Some testimony also referenced a GAO report, with witnesses disagreeing over its meaning and cost-effectiveness. No vote was taken during the discussion, and members asked questions about how the bill would address the workforce shortage and whether a psychiatrist on Kauai could already meet the need. The committee then moved to SB 2271 on hospital licensing and SB 2272 on home health care licensing. The Department of Health, the Healthcare Association of Hawaii, and the Hawaii State Council on Developmental Disabilities supported both measures, which were described as streamlining and clarifying licensing oversight by relying on accreditation or certification reports. A member asked whether the bill language on hospital accreditation reports was duplicative, and the response was that the second provision was intended to strengthen enforcement by requiring hospitals to provide the actual report to DOH. The committee did not take final action in the portion of the hearing provided, and the chair noted that all bills on the agenda would later be considered for decision-making.